STAAR Surgical Company (STAA)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 29/100 (MEDIUM), 200.9 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 18.85% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Why Staar Surgical Zoomed Almost 8% Higher on Tuesday
- STAAR Surgical (STAA) Shares Skyrocket, What You Need To Know
- STAAR Surgical jumps on Stifel upgrade citing China growth potential
- Why Staar Surgical Stock Soared Today
- Sector Update: Healthcare Stocks Edge Higher Premarket Friday
- STAAR Surgical stock ticks higher on $50M buyback authorization
- STAAR Surgical Board Approves $50 Million Share Repurchase Authorization
- China-Led Rebound and New Leadership Might Change The Case For Investing In STAAR Surgical (STAA)
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Safety and Efficacy of AGN-190584 in Individuals With Presbyopia: The GEMINI 1 Phase 3 Randomized Clinical Trial. — JAMA Ophthalmol 2022 Apr 1 PMID 35238902
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for STAAR Surgical Company.
Full STAA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.